Application of genistein benzyl piperazine derivative in diabetes field

A technology of plain benzylpiperazine and genistein, applied in related product fields

Active Publication Date: 2019-02-15
SHANDONG UNIV OF TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] No report on the application of this genistein benzylp

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Establish a diabetic mouse model by injecting streptozotocin (STZ), wherein the injection dose of STZ is 50 mg / d / kg body weight, and the injection lasts for 5 days. L is the criterion for successful modeling. A genistein benzylpiperazine derivative 3.5 mg / kg body weight was administered orally for 30 consecutive days. At the end of the experiment, fasting blood glucose, AMPK, and NF-κB were measured. Compared with the diabetic model group, a genistein benzylpiperazine derivative had a 40.2% activation rate of AMPK and a 16.1% inhibition rate of NF-κB. Significantly reduce the fasting blood glucose level to normal level, the reduction rate reaches 20.1%. Therefore, the application mechanism or pathway of genistein benzylpiperazine derivatives in the field of diabetes is: by activating AMPK and inhibiting NF-κB pathway, thereby significantly reducing fasting blood sugar to normal levels.

Embodiment 2

[0015] Establish a diabetic mouse model by injecting streptozotocin (STZ), wherein the injection dose of STZ is 50 mg / d / kg body weight, and the injection lasts for 5 days. L is the criterion for successful modeling. A genistein benzylpiperazine derivative was administered 5.5 mg / kg body weight for 30 consecutive days. At the end of the experiment, fasting blood glucose, AMPK, and NF-κB were measured. Compared with the diabetic model group, a genistein benzylpiperazine derivative had a 71.2% activation rate of AMPK and a 30.7% inhibition rate of NF-κB. Significantly reduce the fasting blood sugar level to normal level, the reduction rate reaches 26.8%. Therefore, the application mechanism or pathway of genistein benzylpiperazine derivatives in the field of diabetes is: by activating AMPK and inhibiting NF-κB pathway, thereby significantly reducing fasting blood sugar to normal levels.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a genistein benzyl piperazine derivative in the diabetes field. The molecular formula of the genistein benzyl piperazine derivative is C27H28N2O5; the molecular weight of the genistein benzyl piperazine derivative is 460.52; and the name of the genistein benzyl piperazine derivative is 8-((4-(2,4-dimethoxyphenyl)piperazine-1-yl)methyl)-5,7-dyhydroxyl-3-(4-hydroxyphenyl)-4H-benzopyran-4-one. The genistein benzyl piperazine derivative can remarkably reduce the fasting blood glucose level by activating AMPK and inhibiting the NF-kappa B pathway, so as tobe applicable to the diabetes field.

Description

technical field [0001] The invention discloses the application of a genistein benzylpiperazine derivative in the field of diabetes, and belongs to the field of functional food, medicine, tonic and other related products. Background technique [0002] Among chronic diseases, diabetes is an important non-communicable disease that currently threatens global human health. According to the statistics of the International Diabetes Federation, the number of people with diabetes in the world has reached 370 million in 2011, 80% of which are in developing countries. It is estimated that by 2030 the global There will be nearly 550 million people with diabetes. In 2011, a total of 4.6 million people died of diabetes in the world. The current global medical cost of diabetes is 465 billion US dollars. Among them, diabetes is increasing, which has brought a heavy burden to the country's society and economy. [0003] According to the statistics of the 2015 edition of the report on nutriti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61P3/10
CPCA61K31/496A61P3/10
Inventor 盛桂华周泉城
Owner SHANDONG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap